ORAGENICS Business Summary

Oragenics, Inc. (NYSE American: OGEN) is a clinical-stage biopharmaceutical company specializing in the development of brain-targeted therapeutics via proprietary intranasal delivery technology. The company’s business model is primarily focused on the research and development of its lead asset, ONP-002, a first-in-class synthetic neurosteroid designed to treat mild traumatic brain injury (mTBI) and concussions by reducing neuroinflammation and oxidative stress. Revenue generation is currently driven by strategic equity offerings, partnerships with entities like Receptor.AI, and potential future licensing milestones, as the company has no commercialized products. Oragenics operates within the neurology and emergency medicine segments, competing against firms such as Oxeia Biopharmaceuticals, NeuroTrauma Sciences, and larger specialty biotechs like Jazz Pharmaceuticals. It maintains a unique market position as the developer of the only pharmacological treatment for acute concussion currently in Phase 2 clinical trials, addressing a significant unmet medical need in a projected $9 billion market. The executive leadership is anchored by Janet Huffman, who serves as Chief Executive Officer and Chief Financial Officer, leveraging her extensive experience in healthcare finance and operations from TRxADE Health and Banyan Pediatric Care Centers. The scientific and clinical direction is led by Chief Medical Officer Dr. James P. Kelly, a preeminent neurologist and Executive Director of the Marcus Institute for Brain Health, and Chief Clinical Officer Dr. William "Frank" Peacock, a renowned expert in emergency medicine research. Strategic governance is provided by Executive Chairman Charles M. Cherington, a seasoned private equity professional, alongside a board that includes Natasha Giordano, former CEO of PLx Pharma, and long-standing director Dr. Alan Dunton. This team combines deep clinical pedigree in traumatic brain injury with the financial expertise necessary to navigate the capital-intensive clinical trial process.